{"nctId":"NCT04819113","briefTitle":"Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age","startDateStruct":{"date":"2021-04-09","type":"ACTUAL"},"conditions":["Meningococcal Vaccine"],"count":149,"armGroups":[{"label":"Nimenrix","type":"EXPERIMENTAL","interventionNames":["Biological: Nimenrix"]}],"interventions":[{"name":"Nimenrix","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female infants born at \\>36 weeks of gestation and who are 3 months of age (≥76 to ≤104 days) at the time of consent (the day of birth is considered day of life 1).\n* Participants whose parent(s)/legal guardian(s) is willing and able to comply with scheduled visits, treatment plan, and other study procedures.\n* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.\n* Participants who are available for the duration of the study and whose parent(s)/legal guardian(s) can be contacted by telephone during study participation.\n* Participants whose parent(s)/legal guardian(s) is capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Previous anaphylactic reaction to any vaccine or vaccine-related component.\n* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.\n* History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.\n* Significant neurological disorder or history of seizure (including simple febrile seizure).\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* Family history of congenital or hereditary immunodeficiency.\n* Other medical or psychiatric condition, including recent or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* Major known congenital malformation or serious chronic disorder.\n* Previous vaccination with any meningococcal vaccine containing groups A, C, W, or Y.","healthyVolunteers":true,"sex":"ALL","minimumAge":"76 Days","maximumAge":"104 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling and were recorded by the participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 0.0 to 2.0 cm; moderate: \\>2.0 to 7.0 cm; and severe: \\>7.0 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Exact 2-sided confidence interval (CI) was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"13.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":"8.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events included fever, decreased appetite, increased sleep and irritability and were recorded by the participant's parents/legal guardians in an e-diary. Fever was defined as temperature greater than or equal to (\\>=) 38.0 degrees (deg) Celsius (C), categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C; decreased appetite graded as mild: decreased interest in eating, moderate: decreased oral intake and severe: refusal to feed; increased sleep graded as mild: increased or prolonged sleeping bouts, moderate: slightly subdued, interfered with daily activity and severe: disabling, not interested in usual daily activity; irritability graded as mild: easily consolable, moderate: required increased attention and severe: inconsolable, crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"13.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":"30.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"12.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":"34.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2","description":"The use of antipyretic medication was recorded by the participant's parents/legal guardians in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":"47.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 2","description":"An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"13.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 2","description":"An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 30 Days After Vaccination 2","description":"An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2","description":"Immediate AEs were defined as AEs occurring within the first 30 minutes after administration of the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 for Each Serogroup, Neisseria Meningitidis Group (Men) A, MenC, MenW-135 and MenY at Baseline: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline in participants who received vaccinations 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. Analysis was performed on Post Dose (PD) 2 Evaluable Immunogenicity Population (EIP) (PD2 EIP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at 1 Month After Vaccination 1: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at 1 month after vaccination 1 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of rSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at Baseline: Post Dose 2 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of rSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at 1 Month After Vaccination 1: Post Dose 2 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187.2","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of rSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of rSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1818.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1299.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2714.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1667.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling and were recorded by the participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \\>0.0 to 2.0 cm; moderate: \\>2.0 to 7.0 cm; and severe: \\>7.0 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"8.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events included fever, decreased appetite, increased sleep and irritability and were recorded in e-diary. Fever was defined as temperature \\>=38.0 deg C, categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C; decreased appetite graded as mild: decreased interest in eating, moderate: decreased oral intake and severe: refusal to feed; increased sleep graded as mild: increased or prolonged sleeping bouts, moderate: slightly subdued, interfered with daily activity and severe: disabling, not interested in usual daily activity; irritability graded as mild: easily consolable, moderate: required increased attention and severe: inconsolable, crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":"48.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":"32.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1","description":"The use of antipyretic medication was recorded by the participant's parents/legal guardians in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":"31.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With AEs Within 30 Days After Vaccination 1","description":"An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SAEs and NDCMCs: Within 30 Days After Vaccination 1, From 1 Month After Vaccination 1 to 9 Months After Vaccination 1, From Vaccination 1 to 9 Months After Vaccination 1","description":"An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1","description":"Immediate AEs were defined as AEs occurring within the first 30 minutes after administration of the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after Vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. Analysis was performed on post-dose 1 (PD1) evaluable immunogenicity population (EIP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:128 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA titer \\>= 1:128 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of rSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= 1:4 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"Percentage of participants achieving hSBA titers \\>= 1:4 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"Percentage of participants achieving hSBA titers \\>= 1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of hSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at Baseline and 1 Month After Vaccination 1: Post Dose 1 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the hSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Titers >= 1:4 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline, 1 Month After Vaccination 1, at Vaccination 2 and 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving hSBA titers \\>= 1:4 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Titers >= 1:8 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline, 1 Month After Vaccination 1, at Vaccination 2 and 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving hSBA titers \\>= 1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of hSBA Titer for Each of MenA, MenC, MenW-135 and MenY Serogroups at Baseline, 1 Month After Vaccination 1, at Vaccination 2 and 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the hSBA titers (based on the Student t distribution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1208.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7299.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6955.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5062.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving rSBA Titers >= 1:128 for Each Serogroup MenA, MenC, MenW-135 and MenY at Baseline, 1 Month After Vaccination 1, at Vaccination 2 and 1 Month After Vaccination 2: Post Dose 2 Evaluable Immunogenicity Population","description":"Percentage of participants achieving rSBA Titers \\>= 1:128 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in Participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":145},"commonTop":["Irritability (IRRITABILITY)","Hypersomnia (INCREASED SLEEP)","Decreased appetite (DECREASED APPETITE)","Injection site pain (PAIN AT INJECTION SITE)","Erythema (REDNESS)"]}}}